175 related articles for article (PubMed ID: 35477539)
21. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
22. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
23. Stromal responses among common carcinomas correlated with clinicopathologic features.
Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
[TBL] [Abstract][Full Text] [Related]
24. High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival.
Noble P; Vyas M; Al-Attar A; Durrant S; Scholefield J; Durrant L
Br J Cancer; 2013 May; 108(10):2097-105. PubMed ID: 23591201
[TBL] [Abstract][Full Text] [Related]
25. Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.
Sallinger K; Gruber M; Müller CT; Bonstingl L; Pritz E; Pankratz K; Gerger A; Smolle MA; Aigelsreiter A; Surova O; Svedlund J; Nilsson M; Kroneis T; El-Heliebi A
J Transl Med; 2023 Aug; 21(1):528. PubMed ID: 37543577
[TBL] [Abstract][Full Text] [Related]
26. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
[TBL] [Abstract][Full Text] [Related]
27. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
28. Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
Okuyama T; Sameshima S; Takeshita E; Mitsui T; Noro T; Ono Y; Noie T; Ban S; Oya M
BMC Cancer; 2020 Sep; 20(1):842. PubMed ID: 32883261
[TBL] [Abstract][Full Text] [Related]
29. Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients.
Zengin M
Pathol Res Pract; 2019 Nov; 215(11):152635. PubMed ID: 31564570
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Murotani K; Matsui S; Teramukai S; Sugai T; Ajioka Y; Maruo H; Kotaka M; Tsujie M; Munemoto Y; Yamaguchi T; Kuroda H; Fukunaga M; Tomita N; Sugihara K
Br J Cancer; 2021 Mar; 124(6):1088-1097. PubMed ID: 33414540
[TBL] [Abstract][Full Text] [Related]
31. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer.
Bobowicz M; Skrzypski M; Czapiewski P; Marczyk M; Maciejewska A; Jankowski M; Szulgo-Paczkowska A; Zegarski W; Pawłowski R; Polańska J; Biernat W; Jaśkiewicz J; Jassem J
Clin Exp Metastasis; 2016 Dec; 33(8):765-773. PubMed ID: 27485175
[TBL] [Abstract][Full Text] [Related]
33. The Proportion of Tumour-Stroma in Metastatic Lymph Nodes is An Accurately Prognostic Indicator of Poor Survival for Advanced-Stage Colon Cancers.
Zengin M; Benek S
Pathol Oncol Res; 2020 Oct; 26(4):2755-2764. PubMed ID: 32696416
[TBL] [Abstract][Full Text] [Related]
34. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.
Kahlert C; Pecqueux M; Halama N; Dienemann H; Muley T; Pfannschmidt J; Lasitschka F; Klupp F; Schmidt T; Rahbari N; Reissfelder C; Kunz C; Benner A; Falk C; Weitz J; Koch M
Br J Cancer; 2014 Jan; 110(2):441-9. PubMed ID: 24292449
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
Moorman AM; Vink R; Heijmans HJ; van der Palen J; Kouwenhoven EA
Eur J Surg Oncol; 2012 Apr; 38(4):307-13. PubMed ID: 22264965
[TBL] [Abstract][Full Text] [Related]
36. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
40. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
